Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.
0 likes 18mo
Compounds · Retatrutide · continued
What we do not know about retatrutide, listed explicitly posts 61–90
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Building on post #60 rather than restating it.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
22 likes 18mo
SHermansen, post #25: Where I part company with post #23, and it is a narrow parting. Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others. Noting that I have skin in this question… Go to post
No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest answer to most questions here is that the data is not in yet.
That is the version I would defend. It is not the version I started with.
taper_table, post #11: Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either. Go to post
Appreciated. The plain phrasing does more work here than a longer post would.
Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.
If that reads as pedantic, it is, and it has saved me twice.
31 likes 18mo
Retatrutide is investigational. Material obtained outside a clinical trial is research-use-only by definition, is not approved for human use, and carries no assurance about its identity or content beyond whatever independent testing you commission yourself.
A modest claim, modestly supported.
16 likes 18mo
Collapsed as off-topic by two members at trust level 3 or above
Everything in post #63 holds. The case it does not cover is the one I have.
Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The published data does not include such a direct comparison.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
On reflection I would soften that slightly.
0 likes 18mo
No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest answer to most questions here is that the data is not in yet.
It is worth stating the boring hypothesis before the interesting one.
23 likes 18mo
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
Somebody will have a better source than mine, and I hope they post it.
10 likes 18mo
This follows post #70 rather than contradicting it.
The evidence status here should be stated in the first line of any post about it rather than the last. Everything is phase 2 or earlier, and a reader arriving from a search will not know that unless somebody says so.
14 likes 18mo
pe.onwuka, post #14: Post #10 describes the usual case. This is about the unusual one. Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others. I have kept the units in throughout, for… Go to post
Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.
The short version is the first sentence; the rest is why.
m.marchetti, post #30: Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others. Go to post
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
I would want to see it done twice before believing it once.
Coming back to post #72, because the follow-up matters more than the original answer.
Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.
5 likes 18mo
Taking post #74 at face value and following it one step further.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
20 likes 18mo
Post #72 and I disagree about the size of the effect, not about the direction.
Mass and identity: a report on retatrutide should state the mass detected by LC-MS, not assume a theoretical mass. The theoretical mass is not published in peer-reviewed literature for retatrutide at present.
0 likes 18mo
y.adeyemi, post #24: Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either. Go to post
Following, with nothing to contribute beyond having asked the same thing elsewhere.
Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.
This is the sort of thing that ought to be settled and apparently is not.
9 likes 18mo
f.espinoza, post #60: Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either. Go to post
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
I have no interest in any supplier named above.
eire_reader, post #78: Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others. This is the sort of thing that ought to be settled and apparently is not. Go to post
Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.
Post #78 and I disagree about the size of the effect, not about the direction.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
I would hold that lightly until someone with a larger sample weighs in.
4 likes 18mo
Why this subcategory is more cautious than elsewhere: retatrutide is investigational, phase 3 is ongoing, and the heart-rate signal in phase 2 is not negligible. Caution is proportionate to the evidence status.
That is the practical version. The rigorous version is longer and says the same thing.
0 likes 18mo
Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.
Happy to be corrected if someone holds better data than mine.
0 likes 18mo
Okafor, post #3: Everything in the opening post holds. The case it does not cover is the one I have. Mass and identity: a report on retatrutide should state the mass detected by LC-MS, not assume a theoretical mass. The theoretical mass is not published in peer-reviewed literature for retatrutide at present. Go to post
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
gradient_file, post #59: Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others. It took me longer than it should have to see that. Go to post
Post #81 and I disagree about the size of the effect, not about the direction.
A theoretical mass for retatrutide is not published in the peer-reviewed literature in a form worth quoting. A report should state the mass observed on the instrument rather than assert agreement with a figure nobody can check.
Taking post #85 at face value and following it one step further.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
The short answer was in the first line; everything after is the working.
0 likes 18mo
Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.
It cost nothing to check and would have cost something not to.
27 likes 18mo
au.pereira, post #81: Post #78 and I disagree about the size of the effect, not about the direction. Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.… Go to post
Marking my place. If it changes for me I will come back and say so.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
0 likes 18mo
Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.
0 likes 18mo